Status:

COMPLETED

A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Cytomegalovirus Infections

HIV Infections

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

To evaluate the clinical and laboratory toxicity of ganciclovir (GCV) and zidovudine (AZT) when given in combination. Because recent information has shown AZT to be useful in treating AIDS, it is ass...

Detailed Description

Because recent information has shown AZT to be useful in treating AIDS, it is assumed that most patients with AIDS, and probably with AIDS related complex (ARC), will be receiving AZT. Because AZT is ...

Eligibility Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Symptomatic therapy such as analgesics, antihistamines, antiemetics, and antidiarrheal agents, or other supportive therapy may be administered as deemed necessary by the responsible investigator. For fever, the following regimens should be used:
  • If fever above 39.0 degrees C, antipyretic therapy will be administered employing aspirin, 650 mg orally every 4 hours x 3 doses, or until fever falls below 39.0 degrees C.
  • If fever of higher than 39.0 degrees C occurs for 2 consecutive days, the patient may be premedicated with aspirin.

Exclusion Criteria

  • Active alcohol or drug abuse.

Co-existing Condition:

Excluded:

  • Patients with other life-threatening and uncontrolled opportunistic infections on enrollment.

Patients with the following prior conditions are excluded if they:

  • Have other life-threatening and uncontrolled opportunistic infections on enrollment.

Prior Medication:

Excluded within 1 week of study entry:

  • Systemic therapy with antimetabolite.
  • Cytotoxic drug.
  • Interferon.
  • Immunologic modulators.
  • Corticosteroids.
  • Nucleoside analogs other than zidovudine (AZT).
  • Excluded within 2 weeks of study entry:
  • Therapy for any other opportunistic infections.
  • Excluded within 2 months of study entry:
  • Ribavirin.

Prior Treatment:

Excluded within 2 weeks of study entry (for treatment group I):

  • Blood transfusion.
  • Excluded within 1 month of study entry (for treatment groups II and III):
  • Blood transfusion.

All patients must be:

  • Able to provide informed consent.
  • Likely to be available for follow-up for at least 4 months.

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

February 1 1990

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00000995

End Date

February 1 1990

Last Update

November 4 2021

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Univ of California / San Diego Treatment Ctr

San Diego, California, United States, 921036325

2

Bellevue Hosp / New York Univ Med Ctr

New York, New York, United States, 10016

3

Univ of Rochester Medical Center

Rochester, New York, United States, 14642